MKI67 and neuroendocrine neoplasm: Another potential biomarker, Ki-67, has controversial applicability in patients with neuroendocrine tumors (NETs) receiving CAPTEM therapy.3,33,34 Therefore, at present, no biomarker-driven selection criteria for use of the CAPTEM regimen can be recommended.6 In our patient cohort, we found no differences in Ki-67 between response groups, and no correlation with OS or PFS.